JoVE Logo

Zaloguj się

Aby wyświetlić tę treść, wymagana jest subskrypcja JoVE. Zaloguj się lub rozpocznij bezpłatny okres próbny.

W tym Artykule

  • Podsumowanie
  • Streszczenie
  • Wprowadzenie
  • Protokół
  • Wyniki
  • Dyskusje
  • Ujawnienia
  • Podziękowania
  • Materiały
  • Odniesienia
  • Przedruki i uprawnienia

Podsumowanie

This protocol presents a method to evaluate the proteolytic activity of an intrinsically low-activity, single turnover protease in a cellular context. Specifically, this method is applied to evaluate the proteolytic activity of PCSK9, a key driver of lipid metabolism whose proteolytic activity is required for its ultimate hypercholesterolemic function.

Streszczenie

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a single-turnover protease which regulates serum low-density lipoprotein (LDL) levels and, consequently, cardiovascular disease. Although PCSK9 proteolysis is required for its full hypercholesterolemic effect, the evaluation of its proteolytic function is challenging: PCSK9 is only known to cleave itself, undergoes only a single turnover, and after proteolysis, retains its substrate in its active site as an auto-inhibitor. The methods presented here describe an assay which overcomes these challenges. The assay focuses on intermolecular proteolysis in a cell-based context and links successful cleavage to the secreted luciferase activity, which can be easily read out in the conditioned medium. Via sequential steps of mutagenesis, transient transfection, and a luciferase readout, the assay can probe PCSK9 proteolysis under conditions of either genetic or molecular perturbation in a high-throughput manner. This system is well suited for both the biochemical evaluation of clinically discovered missense single-nucleotide polymorphisms (SNPs), as well as for the screening of small-molecule inhibitors of PCSK9 proteolysis.

Wprowadzenie

PCSK9 targets the LDL receptor (LDL-R) for degradation, raising LDL cholesterol (LDL-C) and driving atherosclerotic heart disease1,2. Therapeutics targeting PCSK9 robustly lower LDL-C and improve cardiovascular outcomes for patients, even when added to an aggressive lipid-lowering therapy with statins3,4. Currently approved therapies are limited to antibody-based approaches, however, and suffer from a lack of cost-effectiveness5,6. To solve this problem, less costly therapeutic alternatives, a means to identify patients likely to gain greater benefits, or both, are needed.

Small-molecule approaches could target intracellular PCSK9, provide an improved route of administration, and reduce costs, making them the "Holy Grail" in this area7. However, PCSK9 has proven difficult to drug by small molecules. As a protease, targeting PCSK9's proteolytic function is an attractive strategy, as self-proteolysis is the rate-limiting step of PCSK9 maturation8 and is required for its maximal effect on the LDL-R9. To date, however, this strategy has not been successful, likely due to PCSK9's unique biochemistry: PCSK9 cleaves only itself10, performing a single-turnover reaction, and after self-cleavage, the PCSK9 prodomain remains bound in the active site as an auto-inhibitor11, preventing the readout of any further protease activity.

This article presents a method to evaluate PCSK9 proteolytic function in high-throughput fashion8. Through site-directed mutagenesis, investigators can use this assay to probe the effects of coding SNPs found in the clinic to assess them for effects on proteolysis, the rate-limiting step of PCSK9 maturation. Additionally, this method will be useful in the design of high-throughput screens to identify modulators of PCSK9 proteolysis, which are anticipated to ultimately disrupt the presentation of PCSK9 to the LDL-R (and modulate PCSK9's hypercholesterolemic effect). Lastly, this protocol can be adapted to other proteases with intrinsically low activity, provided that i) a specific substrate-protease pair can be found, and ii) a suitable intracellular anchor can be established for the substrate.

Protokół

1. Site-directed Mutagenesis of Protease Vector

  1. Design and order custom-synthesized oligonucleotides to install a mutation of interest using a modification of standard site-directed mutagenesis protocols12. Standard desalted primers (without additional purification) are perfectly acceptable.
    Note: A general approach to primer designs involves creating partially overlapping primers as indicated in Table 1, using a melting temperature (Tm) calculator specific to the polymerase of interest.
  2. Set up polymerase chain reactions (PCRs) for the site-directed mutagenesis on ice, as indicated in Table 2.
  3. Cycle the PCRs as indicated in Table 3.
  4. Run 2 - 5 µL of each PCR on a 1% agarose gel and visualize the products to confirm a successful amplification.
    Note: A successful PCR will show a single, prominent DNA band at the approximate size marker of the template (~7.8 kB).
  5. Add 0.5 µL (per 25-µL reaction) of DpnI and incubate the samples at 37 °C for 1 h.
  6. Transform 2 µL of the reaction into chemically competent Escherichia coli.
    Note: A fast-growing E. coli strain will reduce incubation times, but any cloning strain will be acceptable.
  7. Plate the transformations onto Luria-Bertani (LB) agar containing 50 - 100 µg/mL carbenicillin. Incubate the plates overnight at 37 °C.
  8. Select 2 - 4 colonies to grow in a small-scale culture (2 - 5 mL of LB medium with 50 - 100 µg/mL carbenicillin). Incubate the culture at 37 °C at 220 rpm until it is turbid.
  9. Isolate the plasmid DNA from the cells using a plasmid DNA purification (i.e., “miniprep”) kit according to the manufacturer’s instructions. Quantify the concentration of eluted DNA using a microvolume spectrophotometer.
  10. Sequence the plasmid DNA extensively using a Sanger sequencing service (such as a core or commercial facility). Prepare the DNA samples according to the service’s specifications. Primers used successfully in prior sequencing reactions are noted in Table 4.
    Note: Due to the PCR amplification of the entire plasmid, the sequencing of the entire PCSK9 coding region is recommended for each mutant.

2. High-throughput Luciferase-based Proteolysis Assay

  1. Cell plating (day 0)
    1. Use low-passage HEK293T cells for experiments and a culture in Dulbecco’s modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS). Perform all cell work under sterile conditions in a tissue culture hood until ready to assay the luciferase activity. Estimate the number of wells and plates needed for the experiment, anticipating that transfections will be performed in triplicate for each condition tested.
    2. Dissociate HEK293T cells from a parent flask by treating them with a minimal volume of 0.05% trypsin-ethylenediaminetetraacetic acid (EDTA) to cover the cells. Inactivate the trypsin-EDTA with 2 volumes of DMEM supplemented with 10% FBS and transfer the cells to a sterile tube. Count the cells using an automated cell counter (and staining with trypan blue). Centrifuge the tube at 500 x g for 5 min to recover cells.
    3. Aspirate trypsin-containing medium and reconstitute the cells in the culture medium to a concentration of 2 x 105 cells/mL. Using a multichannel pipette, transfer 100 µL of the cells to each well of a white (opaque-bottom) 96-well plate, which gives a final seeding concentration of 2 x 104 cells/well.
      Note: For initial experiments, it may be useful to additionally seed a sister, clear-bottom 96-well plate, so as to monitor cell growth and adherence during the protocol and guide future troubleshooting.
    4. Incubate the cells at 37 °C and 5% CO2 for 24 h.
    5. Prepare a master plate of plasmids in a 96-well format. Dilute each plasmid in elution buffer (Tris-HCl, pH 8.5) to 50 ng/µL in an individual well of a 96-well plate.
      1. Prepare 4 wells each for the positive control (WT) plasmid8, negative control (S386A) plasmid8, and plasmid-free buffer (for mock transfections). If drug or other cellular-based treatments are being planned, then prepare the master plate with the positive control (WT) plasmid in each well, along with 4 wells each of the negative control (S386A) plasmid and the plasmid-free buffer.
  2. Transfection (day 1)
    1. Prepare the transfection mixture in a 96-well plate format using deep-well 96-well plates. Perform the transfections in triplicate, being sure to prepare enough reagents to account for pipetting and transfer losses.
      Note: The following calculations prepare enough reagent to run one 96-well plate in triplicate (estimated conservatively for 420 wells).
      1. Make a master mix of a diluted lipid transfection reagent, adding 50.4 µL of reagent to 2050 µL of reduced-serum medium. Make a master mix of a DNA precomplexation reagent, adding 33.6 µL of reagent into 1730 µL of reduced-serum medium.
      2. Using a multichannel pipette, aliquot 16.8 µL of the diluted DNA precomplexation reagent mixture into each well of the deep-well plate.
      3. Using a multichannel pipette, aliquot 3.2 µL (160 ng) of each plasmid from the master plate into each well of the deep-well plate.
      4. Using a multichannel pipette, aliquot 20 µL of the diluted lipid transfection reagent mixture to each well of the plate and mix the contents of each well using the multichannel pipette. Cover the plates and let them sit at room temperature (RT) for 10 - 15 min to form lipid:DNA complexes.
        Note: Upon transfection, the final components per well will be as follows: 40 ng of DNA, 0.12 µL of transfection reagent, and 0.08 µL of DNA pre-complexation reagent, and the content of each well will be 10 µL in total volume (reduced-serum medium).
    2. Gently exchange the medium on the 293T cells in the 96-well plates using a multichannel pipette, taking care not to disrupt the cells. Replace the aspirated medium with 95 µL of DMEM supplemented with 10% FBS.
      Note: This would be an appropriate time to treat the cells with any drug of interest.
    3. Add 10 µL of the transfection mixture to each appropriate well via a multichannel pipette. Gently swirl the plate to mix the contents in the wells. Incubate the plate at 37 °C with 5% CO2 for 24 h.
      Note: The final volume of the wells comes to 105 µL, to account for evaporation over 24 h.
  3. Assay (day 2)
    1. Prepare a stock solution for coelenterazine reagents: 3 M sodium ascorbate [dissolved in phosphate-buffered saline (PBS), prepared fresh], 5 M NaCl, 10 mg/mL bovine serum albumin (BSA; dissolved in PBS, prepared fresh), and 2 mM coelenterazine (dissolved in acidified methanol containing 200 µL of 3 N HCl per 10 mL).
      Note: The 2 mM coelenterazine can be stored for 2 weeks when it is kept at -80 °C and in the absence of light.
    2. Prepare 2x coelenterazine reagents for the luciferase readout, with a separate reagent each for the cells and medium, according to Table 5. Mix all reagents save the coelenterazine first, filter the mixture through a 0.22-µm syringe filter, and then add the coelenterazine. Protect the reagents from light until they are ready to be added to the plates.
      Note: Due to the loss of solution from filtration, make enough reagent to account for both the loss from filtration, as well as from transfers. Table 5 shows the final concentration of the 2x reagents (as well as the amount of stock solution to add to read out one 96-well plate with one reagent).
    3. Remove the cells from the incubator 24 h after the transfection. Using a multichannel pipette, transfer 50 µL of conditioned medium from each well to a fresh, white-bottomed (opaque) 96-well plate.
      1. Label the plates as to whether they contain medium or cells. If more than one 96-well plate was transfected, label the plates so as to ensure that each medium-containing plate is paired with its parent plate of cells.
    4. Using a multichannel pipette, add 50 µL of 2x non-lytic coelenterazine reagent to the plate containing only conditioned medium. Gently rock or shake the plate in the absence of light for 5 - 10 min at RT.
    5. Using a multichannel pipette, add 50 µL of 2x lytic coelenterazine reagent to the plate containing the cells. Gently rock or shake the plate in the absence of light for 5 - 10 min at RT.
    6. After the incubation, read out the luminescence of the medium-only plate in a plate reader. Then, read out the luminescence of the cell-containing plate in the same plate reader.
    7. Discard the plates and save the files for data analysis.

3. Data Analysis

  1. Perform an initial data analysis using spreadsheet software. Create a spreadsheet containing the results from the cell and the medium plates.
  2. Manually inspect the data from the cell plates to identify poorly transfected wells. Wells that show < 5% - 10% of the readout of the negative control (S386A) plasmid should be considered as poorly transfected, making the interpretation of those data suspect.
  3. Calculate the average background luminescence of each plate from the mock-transfected wells. Subtract the background of each plate from the values of that plate.
    Note: This value may be negligible depending on the plate reader used.
  4. Process the data by calculating the proportion of luciferase activity in the medium compared to the overall luciferase activity for each well. Because the cell plate contains both conditioned medium in addition to cells, and the medium-only plate contains the same amount of conditioned medium as the cell plate, it is appropriate to use the following equation:
    figure-protocol-10473
    Here, RLU = relative luminescence units, the background-subtracted readout from the plate reader.
  5. Calculate the mean secreted luciferase of the positive control (WT) and the negative control (S386A) wells.
  6. Evaluate the overall quality of the experiment by calculating a Z-factor13:
    figure-protocol-10881
    Note: The active values come from the positive control (WT) and the inactive values come from the negative control (S386A) wells. Values closer to 1 indicate a higher experimental quality. Consider repeating the experiment or optimizing the workflow if the value is below 0.
  7. Transfer the data from the spreadsheet program into scientific data analysis software.
  8. Normalize the secreted luciferase activity to the mean values of the positive control (WT) and the negative control (S386A), setting the positive control as 1 and the negative control as 0.
  9. Clean the data for outliers using the regression and outlier removal (ROUT) method, setting the maximum false discovery rate to 1%.
  10. Evaluate for statistically significant differences by comparing the data for each mutant condition (or mutant) to the mean of the WT activity (normalized to a value of 1). Perform multiple unpaired t-tests, correcting for multiple comparisons using the Holm-Sidak method and α = 0.05.

Wyniki

The high-throughput proteolysis assay relies upon overcoming three major challenges. First, to overcome the intrinsically low output of a single-turnover PCSK9 protease, a PCSK9 protease lacking the inhibitory prodomain is used, with the cleavage sequence at the tail of the prodomain linked to a luciferase that can be secreted14. Second, to satisfy the need for the protease to fold in complex with its inhibitory prodomain, the two polypeptides are coexpressed i...

Dyskusje

The experimental procedures described above present a method to overcome the intrinsically low activity of the single-turnover protease PCSK9 and evaluate its proteolytic function in a robust manner. The key concept of the assay relies upon converting a single-turnover event into an enzymatically amplified readout. The strengths of the assay include the relatively short time-frame and ease of use of the luciferase reporter, as well as its scalability to high-throughput approaches. In addition, the assay evaluates proteol...

Ujawnienia

The authors have nothing to disclose.

Podziękowania

The authors thank the generous funding support from the NHLBI/NIH (K08 HL124068 and LRP HMOT1243), NCATS/NIH through the UCSF Clinical and Translational Science Institute Catalyst Program (UL1 TR000004), the UCSF Academic Senate, the Hellman Foundation, a Gilead Sciences Research Scholar Award, a Pfizer ASPIRE Cardiovascular Award (all to John S. Chorba) and the Howard Hughes Medical Institute (to Adri M. Galvan and Kevan M. Shokat).

Materiały

NameCompanyCatalog NumberComments
PCR TubesUSA Scientific1402-2900For PCR
Q5 Hot StartNew England BiolabsM0493LHigh-fidelity DNA Polymerase
Deoxynucleotide Solution MixNew England BiolabsN0447LdNTPs (for PCR)
pPCSK9-NLucProteaseAssay-WTAuthorsn/aAvailable from authors
pPCSK9-NLucProteaseAssay-S386AAuthorsn/aAvailable from authors
Agarose LEGold BiotechnologyA-201-100For DNA gels
E-Gel Imager System with Blue Light BaseThermoFisher Scientific4466612For imaging DNA gels
SYBR Safe DNA Gel StainThermoFisher ScientificS33102For DNA gels
Tris BaseThermoFisher ScientificBP152-1For DNA gel running buffer
Glacial acetic acidThermoFisher ScientificA38-500For DNA gel running buffer
Ethylenediaminetetraacetic acid solutionMillipore Sigma3690EDTA, for DNA gel running buffer
1 kb DNA ladderGold BiotechnologyD010DNA ladder
DpnINew England BiolabsR0176SRestriction enzyme
LB Agar plates with 100 µg/mL carbenicillinTeknovaL1010LB-Carb plates
One Shot Mach1 T Phage-Resistent Chemically Competent E. coliThermoFisher ScientificC862003Chemically competent cells
LB Broth, MillerThermoFisher ScientificBP1426-2LB
CarbenicillinGold BiotechnologyC-103-5Selective antibiotic
E.Z.N.A. Plasmid Mini Kit IOmega BioTekD6942-02DNA Purification Miniprep kit
NanoDrop 2000 SpectrophotomerThermoFisher ScientificND-2000CSpectrophotometer
293T CellsAmerican Tissue Culture Collection (ATCC)CRL-3216HEK 293T cells
DMEM, high glucose, pyruvateThermoFisher Scientific11995065DMEM, mammalian cell media
Fetal Bovine SeraAxenia BiologixF001FBS
Trypsin-EDTA (0.05%), phenol redThermoFisher Scientific25300062Trypsin, for cell dissociation
Phosphate buffered saline (PBS)ThermoFisher Scientific10010023PBS
Countess automated cell counterThermoFisher ScientificC10227Automated cell counting
Countess cell counting chamber slidesThermoFisher ScientificC10228Slides for cell counting
CELLSTAR Tissue Culture Plates, White, White-Bottom, with LidGrenier Bio-One655083White, white-bottom 96 well plate
TempPlate non-skirted 96-well PCR plate, naturalUSA Scientific1402-959696 well plate for master plasmid plate
Nunc 2.0mL DeepWell PlatesThermoFisher Scientific27874396 well deep well plate
Lipofectamine 3000ThermoFisher ScientificL3000008Lipid transfection reagent, Lf3K
P3000 ReagentThermoFisher ScientificL3000008DNA pre-complexation reagent, provided with Lf3K
OptiMEM I Reduced Serum MediumThermoFisher Scientific31985062Reduced serum medium for transfection
(+)-Sodium L-ascorbateMillipore SigmaA4034Sodium ascorbate
Sodium chlorideMillipore SigmaS9888NaCl
Albumin, Bovine Serum, Fraction V, Low Heavy MetalsMillipore Sigma12659BSA
Methanol (HPLC)ThermoFisher ScientificA4524MeOH
Hydrochloric acidVWRJT9535-2Concentrated HCl
CoelenterazineGold BiotechnologyCZ2.5Luciferase substrate
Syringe Filter, SterileThermoFisher Scientific09-720-3Sterile filter, PVDF, 0.22 µm pore
Pipet-Lite Multi Pipette L12-200XLS+Rainin17013810Multichannel pipette
Pipet-Lite Multi Pipette L12-20XLS+Rainin17013808Multichannel pipette
Pipet-Lite Multi Pipette L12-10XLS+Rainin17013807Multichannel pipette
Reagent reservoirCorning4870Trough for reagents
Centrifuge tubes, 15 mLThermoFisher Scientific05-539-1215 mL tubes
Centrifuge tubes, 50 mLCorning43082950 mL tubes
Spark Microplate ReaderTecanN/aPlate Reader
ExcelMicrosoft2016 for MacSpreadsheet software
PrismGraphPad Softwarev7Scientific data analysis software

Odniesienia

  1. Park, S. W., Moon, Y. A., Horton, J. D. Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver. Journal of Biological Chemistry. 279 (48), 50630-50638 (2004).
  2. Cohen, J. C., Boerwinkle, E., Mosley, T. H., Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. New England Journal of Medicine. 354 (12), 1264-1272 (2006).
  3. Ridker, P. M., et al. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine. 376 (16), 1527-1539 (2017).
  4. Sabatine, M. S., et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. New England Journal of Medicine. 376 (18), 1713-1722 (2017).
  5. Kazi, D. S., et al. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. Journal of the American Medical Association. 316 (7), 743-753 (2016).
  6. Kazi, D. S., et al. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial. Journal of the American Medical Association. 318 (8), (2017).
  7. Pettersen, D., Fjellström, O. Small molecule modulators of PCSK9 - A literature and patent overview. Bioorganic & Medicinal Chemistry Letters. 28 (7), 1155-1160 (2018).
  8. Chorba, J. S., Galvan, A. M., Shokat, K. M. Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype. Journal of Biological Chemistry. 293 (6), 1875-1886 (2018).
  9. Maxwell, K. N., Breslow, J. L. Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. Proceedings of the National Academy of Sciences of the United States of America. 101 (18), 7100-7105 (2004).
  10. Benjannet, S., et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. Journal of Biological Chemistry. 279 (47), 48865-48875 (2004).
  11. Cunningham, D., et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nature Structural & Molecular Biology. 14 (5), 413-419 (2007).
  12. Liu, H., Naismith, J. H. An efficient one-step site-directed deletion, insertion, single and multiple-site plasmid mutagenesis protocol. BMC Biotechnology. 8, 91 (2008).
  13. Zhang, J., Chung, T., Oldenburg, K. A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. Journal of Biomolecular Screening. 4 (2), 67-73 (1999).
  14. Hall, M. P., et al. Engineered luciferase reporter from a deep sea shrimp utilizing a novel imidazopyrazinone substrate. ACS Chemical Biology. 7 (11), 1848-1857 (2012).
  15. McNutt, M. C., Lagace, T. A., Horton, J. D. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. Journal of Biological Chemistry. 282 (29), 20799-20803 (2007).
  16. Chorba, J. S., Shokat, K. M. The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis. Journal of Biological Chemistry. 289 (42), 29030-29043 (2014).
  17. Benjannet, S., Rhainds, D., Hamelin, J., Nassoury, N., Seidah, N. G. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. Journal of Biological Chemistry. 281 (41), 30561-30572 (2006).
  18. Zhao, Z., et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. American Journal of Human Genetics. 79 (3), 514-523 (2006).

Przedruki i uprawnienia

Zapytaj o uprawnienia na użycie tekstu lub obrazów z tego artykułu JoVE

Zapytaj o uprawnienia

Przeglądaj więcej artyków

PCSK9ProteolysisLuciferase AssayHigh throughputAtherosclerotic Heart DiseaseProteaseHEK293T CellsTransfectionCell CultureBiochemical System

This article has been published

Video Coming Soon

JoVE Logo

Prywatność

Warunki Korzystania

Zasady

Badania

Edukacja

O JoVE

Copyright © 2025 MyJoVE Corporation. Wszelkie prawa zastrzeżone